Efficacy and safety of oral Pentasa (prolonged-release mesalazine) in mild-to-moderate ulcerative colitis: a systematic review and meta-analysis

References

• Kobayashi T, Siegmund B, Le Berre C, et al. Ulcerative colitis. Nat Rev Dis Prim. 2020;6:74.
   PubMed Web of Science ®Google Scholar
• Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN study). Scand J Gastroenterol. 2009;44(4):431–440.
   PubMed Web of Science ®Google Scholar
• Ungaro R, Colombel J-F, Lissoos T, et al. A treat-to-target update in ulcerative colitis: a systematic review. Am J Gastroenterol. 2019;114(6):874–883.
   PubMed Web of Science ®Google Scholar
• Colombel J-F, D’haens G, Lee W-J, et al. Outcomes and strategies to support a treat-to-target approach in inflammatory bowel disease: a systematic review. J Crohns Colitis. 2020;14(2):254–266.
   PubMed Web of Science ®Google Scholar
• Harbord M, Eliakim R, Bettenworth D, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis. 2017;11(7):769–784.
   PubMed Web of Science ®Google Scholar
• Ko CW, Singh S, Feuerstein JD, et al. AGA clinical practice guidelines on the management of mild-to-moderate ulcerative colitis. Gastroenterology. 2019;156(3):748–764.
   PubMed Web of Science ®Google Scholar
• Fumery M, Singh S, Dulai PS, et al. Natural history of adult ulcerative colitis in population-based cohorts: a systematic review. Clin Gastroenterol Hepatol. 2018;16(3):343–356.e3.
   PubMed Web of Science ®Google Scholar
• Ye B. Mesalazine preparations for the treatment of ulcerative colitis: are all created equal? World J Gastrointest Pharmacol Ther. 2015;6(4):137.
   PubMedGoogle Scholar
• Farup PG, Hinterleitner TA, Lukáš M, et al. Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis. Inflamm Bowel Dis. 2001;7(3):237–242.
   PubMed Web of Science ®Google Scholar
• Marteau P, Probert CS, Lindgren S, et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut. 2005;54(7):960–965.
   PubMed Web of Science ®Google Scholar
• Miner P, Hanauer S, Robinson M, et al. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Digest Dis Sci. 1995;40(2):296–304.
   PubMed Web of Science ®Google Scholar
• Dignass AU, Bokemeyer B, Adamek H, et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol. 2009;7(7):762–769.
   PubMed Web of Science ®Google Scholar
• Feagan BG, MacDonald JK. Once daily oral mesalamine compared to conventional dosing for induction and maintenance of remission in ulcerative colitis: a systematic review and Meta-analysis. Inflamm Bowel Dis. 2012;18(9):1785–1794.
   PubMed Web of Science ®Google Scholar
• Flourié B, Hagège H, Tucat G, et al. Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis. Aliment Pharmacol Ther. 2013;37(8):767–775.
   PubMed Web of Science ®Google Scholar
• D'Haens GR, Sandborn WJ, Zou G, et al. Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis. Aliment Pharmacol Ther. 2017;46(3):292–302.
   PubMed Web of Science ®Google Scholar
• Barberio B, Segal JP, Quraishi MN, et al. Efficacy of oral, topical, or combined oral and topical 5-aminosalicylates, in ulcerative colitis: systematic review and network meta-analysis. J Crohns Colitis. 2021;15:1184–1196.
   PubMed Web of Science ®Google Scholar
• Murray A, Nguyen TM, Parker CE, et al. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2020;8:CD000543.
   PubMed Web of Science ®Google Scholar
• Murray A, Nguyen TM, Parker CE, et al. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2020;8:CD000544.
   PubMedGoogle Scholar
• Paez A. Gray literature: an important resource in systematic reviews. J Evid Based Med. 2017;10(3):233–240.
   PubMedGoogle Scholar
• Wilding IR, Kenyon CJ, Hooper G. Gastrointestinal spread of oral prolonged-release mesalazine microgranules (PENTASA) dosed as either tablets or sachet. Aliment Pharmacol Ther. 2000;14(2):163–169.
   PubMed Web of Science ®Google Scholar
• Ferring Pharmaceuticals. 3.2.P.2 Pharmaceutical Development (Version 6). 2013.
   Google Scholar
• Higgins JPT, Altman DG, Sterne JAC. Chapter 8: assessing risk of bias in included studies. In: Higgins JPT, Green S, editor. Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011). The Cochrane Collaboration. 2011. Available from: www.handbook.cochrane.org
   Google Scholar
• Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1–12.
   PubMedGoogle Scholar
• Viswanathan M, Berkman ND, Dryden DM, et al. Assessing risk of bias and confounding in observational studies of interventions or exposures: further development of the RTI item bank. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013.
   Google Scholar
• Kamm MA, Sandborn WJ, Gassull M, et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology. 2007;132(1):66–75.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Kamm MA, Boddu P, et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol. 2007;5(1):95–102.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Sandborn WJ, D’Haens G, et al. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology. 2013;145(1):149–157.e2.
   PubMed Web of Science ®Google Scholar
• Deeks JJ, Higgins JPT, Altman DG, editors. Chapter 10: analysing data and undertaking Meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane handbook for systematic reviews of interventions version 6.2 (updated February 2021). Cochrane; 2021. Available from: www.training.cochrane.org/handbook
   Google Scholar
• Hanauer S, Schwartz J, Robinson M, et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Am J Gastroenterol. 1993;88:1188–1197.
   PubMed Web of Science ®Google Scholar
• Ito H, Iida M, Matsumoto T, et al. Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study. Inflamm Bowel Dis. 2010;16(9):1567–1574.
   PubMed Web of Science ®Google Scholar
• Gibson PR, Fixa B, Pekarkova B, et al. Comparison of the efficacy and safety of Eudragit-L-coated mesalazine tablets with ethylcellulose-coated mesalazine tablets in patients with mild to moderately active ulcerative colitis. Aliment Pharmacol Ther. 2006;23(7):1017–1026.
   PubMed Web of Science ®Google Scholar
• Mulder CJJ, Tytgat GNJ, Weterman IT, et al. Double-blind comparison of slow-release 5-aminosalicylateand sulfasalazine in remission maintenance in ulcerative colitis. Gastroenterology. 1988;95(6):1449–1453.
   PubMed Web of Science ®Google Scholar
• Campieri M, Gionchetti PB, et al. Slow-release 5-aminosalicylic acid (PENTASA) versus sulphasalazine (SASP) in the maintenance treatment of ulcerative colitise. Scand J Gastroenterol. 1989;24:130.
   PubMed Web of Science ®Google Scholar
• Desideri S, Ardizzone S, Petrillo M. Two different oral formulations of 5-Aminosalicylic acid (5-ASA) in maintenance treatment of ulcerative colitis. Ital J Gastroenterol. 1991;23:643.
   Google Scholar
• Ito H, Iida M, Matsumoto T, et al. Direct comparison of two different mesalamine formulations for the maintenance of remission in patients with ulcerative colitis: a double-blind, randomized study. Inflamm Bowel Dis. 2010;16(9):1575–1582.
   PubMed Web of Science ®Google Scholar
• Nagahori M, Kochi S, Hanai H, et al. Real life results in using 5-ASA for maintaining mild to moderate UC patients in Japan, a multi-center study, OPTIMUM Study. BMC Gastroenterol. 2017;17(1):47.
   PubMed Web of Science ®Google Scholar
• Ham M, Moss AC. Mesalamine in the treatment and maintenance of remission of ulcerative colitis. Expert Rev Clin Pharmacol. 2012;5(2):113–123.
   PubMed Web of Science ®Google Scholar
• Safdi M, Schwartz J, Kaplan M, et al. Controlled-release mesalamine capsules for the treatment of ulcerative colitis: final results of a multicenter open-label trial. Am J Gastroenterol. 1991;16:A284.
   Google Scholar
• Fockens P, Mulder CJJ, Tytgat GNJ, et al. Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group. Eur J Gastroenterol Hepatol. 1995;7(11):1025–1030.
   PubMed Web of Science ®Google Scholar
• Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1–s106.
   PubMed Web of Science ®Google Scholar
• Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019;114(3):384–413.
   PubMed Web of Science ®Google Scholar
• Probert CS, Dignass AU, Lindgren S, et al. Combined oral and rectal mesalazine for the treatment of mild-to-moderately active ulcerative colitis: rapid symptom resolution and improvements in quality of life. J Crohns Colitis. 2014;8(3):200–207.
   PubMed Web of Science ®Google Scholar
• Robinson M, Hanauer S, Hoop R, et al. Mesalamine capsules enhance the quality of life for patients with ulcerative colitis. Aliment Pharmacol Ther. 2007;8(1):27–34.
   Google Scholar
• Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2006;23(5):577–585.
   PubMed Web of Science ®Google Scholar
• Watanabe M, Hanai H, Nishino H, et al. Comparison of QD and TID oral mesalazine for maintenance of remission in quiescent ulcerative colitis: a double-blind, double-dummy, randomized multicenter study. Inflamm Bowel Dis. 2013;19(8):1681–1690.
   PubMed Web of Science ®Google Scholar
• Solitano V, D’Amico F, Fiorino G, et al. Key strategies to optimize outcomes in mild-to-moderate ulcerative colitis. J Clin Med. 2020;9:2905.
   PubMed Web of Science ®Google Scholar